Superworth

Fortrea profit margin FTRE

Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.

Net margin, 12 months
−3.2%
Operating margin, 12 months
−0.4%
Net margin on a year earlier
+34.4 pts
Peer median
10.6%

Over the twelve months to Jun 30, 2026, Fortrea kept −3.2% of its revenue as net profit, with an operating margin of −0.4% and a gross margin of 19.3%.

The median for 9 diagnostics and research stocks of a similar size is 10.6%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−36.2%−32.0%18.5%
FY2024−12.2%−6.0%19.8%
FY2023−0.9%1.1%20.8%
FY20226.2%7.6%21.0%

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−3.2%+34.4 pts−0.4%
Q1 FY26−16.5%+12.9 pts−13.1%
Q4 FY25−36.2%−24.0 pts−32.0%
Q3 FY25−36.8%−24.9 pts−33.1%
Q2 FY25−37.6%−26.4 pts−33.8%
Q1 FY25−29.4%−24.5 pts−24.0%
Q4 FY24−12.2%−11.3 pts−6.0%
Q3 FY24−11.9%−14.0 pts−4.8%
Q2 FY24−11.2%−15.9 pts−3.7%
Q1 FY24−4.9%−10.7 pts−0.7%
Q4 FY23−0.9%−7.1 pts1.1%
Q3 FY232.2%n/a4.1%

Against its peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first, today.

CompanyProfit margin
FTREFortrea−3.2%
CDNACareDx24.2%
VCYTVeracyte20.4%
BLLNBillionToOne9.5%
LNTHLantheus17.7%
CAICaris Life Sciences10.6%
BIOBio-Rad Laboratories8.6%
NRCNRC Health4.2%
RVTYRevvity8.2%
MEDPMedpace17.7%
Peer median10.6%

Where Fortrea ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Fortrea

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.